Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Double-Dummy, Two-Way Cross-Over, Randomised, Phase II Study of Efficacy, Safety and Tolerability of Modified-Release Hydrocortisones: Chronocort Versus Plenadren, in Adrenal Insufficiency

Next Previous
Trial Profile

A Double-Blind, Double-Dummy, Two-Way Cross-Over, Randomised, Phase II Study of Efficacy, Safety and Tolerability of Modified-Release Hydrocortisones: Chronocort Versus Plenadren, in Adrenal Insufficiency

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydrocortisone (Primary) ; Hydrocortisone
  • Indications Adrenal insufficiency
  • Focus Proof of concept; Therapeutic Use
  • Acronyms The CHAMPAIN Study
  • Sponsors Diurnal

Most Recent Events

  • 08 May 2025 According to a Neurocrine Biosciences media release, data from CHAMPAIN trial, will be presented at the 2025 Joint Congress of European Society for Paediatric Endocrinology and the European Society of Endocrinology in Copenhagen, Denmark.
  • 03 Jun 2024 According to a Neurocrine Biosciences media release, data form this trial were presented at the Endocrine Society Annual Meeting, ENDO 2024 and published in an online edition of The New England Journal of Medicine.
  • 28 May 2024 According to a Neurocrine Biosciences media release, results will be presented at the Endocrine Society Annual Meeting (ENDO 2024) in Boston, June 1-4.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top